Gynuity Health Projects, 220 E. 42nd Street, Suite 710, New York, NY 10017, USA.
The Women's Centers, 777 Appletree Street, 7th Floor, Philadelphia, PA 19106, USA.
Contraception. 2020 May;101(5):302-308. doi: 10.1016/j.contraception.2020.01.009. Epub 2020 Feb 1.
This open-label non-inferiority study assessed efficacy of a common outpatient medical abortion regimen among people with pregnancies 64-70 days and 71-77 days of gestation.
We defined non-inferiority by a 6% margin of method success. People with intrauterine pregnancies 64-77 days' gestational age by abdominal ultrasound seeking medical abortion at one of eight clinics and met eligibility criteria were offered participation. Consenting participants took mifepristone 200 mg followed 24-48 h later by misoprostol 800 mcg buccally, and returned after one week for provider evaluation and abdominal ultrasound to determine abortion status. Participants recorded medication use, pregnancy expulsion, daily bleeding and pain scores until the one-week follow up. Clinic staff interviewed participants prior to study discharge to assess acceptability.
Seven hundred and nineteen participants were enrolled, 393 and 326 in the respective groups. Successful expulsion without surgical intervention was achieved in 92.3% of the earlier gestational age group and 86.7% of the later group (difference in proportions 5.6%, 1-sided 95% CI 9.6). Ongoing pregnancy accounted for 3.6% and 8.7% (p = 0.007) of outcomes, respectively. Participants in the 71-77 day group reported nausea and weakness more frequently. Pain, bleeding and acceptability measures between groups were similar.
Although the success rate at 71-77 days of gestation was within the non-inferiority margin, we cannot rule out that it is statistically worse than in the previous gestational week. Significantly more ongoing pregnancies in the later group raise concerns about using the regimen at 71-77 days.
本开放性标签非劣效性研究评估了在妊娠 64-70 天和 71-77 天的人群中,一种常见的门诊药物流产方案的疗效。
我们通过 6%的方法成功率来定义非劣效性。在八家诊所之一寻求药物流产的宫内妊娠 64-77 天经腹部超声符合纳入标准的人群被邀请参与。同意参与的参与者服用米非司酮 200mg,24-48 小时后经口腔给予米索前列醇 800mcg,并在一周后返回进行提供者评估和腹部超声以确定流产状态。参与者记录药物使用、妊娠排出、每日出血和疼痛评分,直到一周随访。诊所工作人员在研究出院前对参与者进行访谈,以评估可接受性。
共有 719 名参与者入组,分别有 393 名和 326 名参与者在各自的组中。较早妊娠组的成功排出率为 92.3%,较晚妊娠组为 86.7%(比例差异 5.6%,单侧 95%CI 9.6%)。持续性妊娠分别占 3.6%和 8.7%(p=0.007)。71-77 天组的参与者报告恶心和乏力更为频繁。两组之间的疼痛、出血和可接受性措施相似。
虽然 71-77 天妊娠的成功率在非劣效性范围内,但我们不能排除其在统计学上比前一周更差。在较晚的妊娠组中,持续性妊娠的比例显著增加,这引起了对在 71-77 天使用该方案的担忧。